The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.
 
Wael A. Harb
Employment - Horizon Oncology Research; Horizon Oncology Research (I)
Leadership - Horizon Oncology Research (I)
Stock and Other Ownership Interests - Horizon Oncology Research
Consulting or Advisory Role - ProNAi (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Threshold Pharmaceuticals
 
Amy M. Weise
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Celldex (Inst); EMD Serono (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Justin Anthony Call
No Relationships to Disclose
 
Arkadiusz Z. Dudek
Employment - Adhaere Pharmaceuticals
Leadership - IGF Oncology; Martell diagnostic
Stock and Other Ownership Interests - Adhaere Pharmaceuticals; Biothera; IGF Oncology; Vanquish Oncology
Honoraria - Biothera; IGF Oncology; Medtronic; Vanquish Oncology
Consulting or Advisory Role - Biothera; TTC Oncology; Vanquish Oncology
 
Rene Gonzalez
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Celldex (Inst); Checkmate Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Reata Pharmaceuticals (Inst); Syndax (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech; Novartis
 
C. Lance Cowey
Honoraria - Bristol-Myers Squibb; Genentech; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Genentech; Novartis
Research Funding - Bristol-Myers Squibb; Genentech; Merck; Novartis
 
P. Taylor Eves
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
 
Ashwin Gollerkeri
Employment - Array BioPharma; Pfizer
Stock and Other Ownership Interests - Array BioPharma
Patents, Royalties, Other Intellectual Property - Yale University (I)
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech; Loxo; Novartis; Theravance
Research Funding - Adaptimmune; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech; Merck; Novartis
Travel, Accommodations, Expenses - Affymetrix